Lisata Therapeutics
LSTA
31 hedge funds and large institutions have $3.7M invested in Lisata Therapeutics in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 6 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
3.78% less ownership
Funds ownership: 15.75% → 11.96% (-3.8%)
11% less funds holding
Funds holding: 35 → 31 (-4)
48% less capital invested
Capital invested by funds: $7.09M → $3.7M (-$3.39M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$493K |
| 2 |
CL
CSS LLC
Chicago,
Illinois
|
+$173K |
| 3 |
Jane Street
New York
|
+$66.7K |
| 4 |
VF
Virtu Financial
New York
|
+$59K |
| 5 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$50K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$660K |
| 2 |
PCM
PenderFund Capital Management
Vancouver,
British Columbia, Canada
|
-$238K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$58.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$25.4K |
| 5 |
DAM
Deltec Asset Management
New York
|
-$24.2K |
LSTA Hedge Fund Activity: Q2 2026 in Review
31 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q2 2026, worth a combined $3.7M — down 48% from $7.09M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LSTA and 3 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was Yakira Capital Management, opening a new position worth an estimated $493K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $660K sold.
- 31 institutional investors held Lisata Therapeutics (LSTA) as of Q2 2026, down from 35 in Q1 2026.
- Funds reported $3.7M of Lisata Therapeutics stock for Q2 2026, down 48% quarter-over-quarter.
- 3 funds opened new Lisata Therapeutics positions in Q2 2026 and 6 closed out, a net change of -3 holders.
- The largest Lisata Therapeutics buyer in Q2 2026 was Yakira Capital Management, an estimated $493K added.
- The largest Lisata Therapeutics seller in Q2 2026 was Renaissance Technologies, an estimated $660K sold.
Based on aggregated 13F filings for Q2 2026.